| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS42001196 | EBV | ENSG00000149925.22 | protein_coding | ALDOA | No | No | 226 | P04075 |
| TVIS44017885 | HTLV-1 | ENSG00000149925.22 | protein_coding | ALDOA | No | No | 226 | P04075 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | ALDOA |
|---|---|
| DrugBank ID | DB04326 |
| Drug Name | Dihydroxyacetone phosphate |
| Target ID | BE0001683 |
| UniProt ID | P04075 |
| Regulation Type | |
| PubMed IDs | 17139284; 17016423; 10592235 |
| Citations | Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.@@Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.@@Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. |
| Groups | Investigational |
| Direct Classification | Monosaccharide phosphates |
| SMILES | OCC(=O)COP(O)(O)=O |
| Pathways | De Novo Triacylglycerol Biosynthesis TG(16:0/16:1(9Z)/18:2(9Z,12Z)); De Novo Triacylglycerol Biosynthesis TG(16:0/18:2(9Z,12Z)/18:2(9Z,12Z)); De Novo Triacylglycerol Biosynthesis TG(16:0/18:0/20:4(5Z,8Z,11Z,14Z)); Glycogenosis, Type IB; Fructose and Mannose Degradation; De Novo Triacylglycerol Biosynthesis TG(16:0/16:1(9Z)/18:1(9Z)); De Novo Triacylglycerol Biosynthesis TG(20:0/20:0/20:1(11Z)); De Novo Triacylglycerol Biosynthesis TG(18:0/20:1(11Z)/20:1(11Z)); Glycerol Phosphate Shuttle; De Novo Triacylglycerol Biosynthesis TG(16:0/20:0/20:0); De Novo Triacylglycerol Biosynthesis TG(18:0/18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z)); Glycolysis; De Novo Triacylglycerol Biosynthesis TG(16:0/16:0/16:0); De Novo Triacylglycerol Biosynthesis TG(16:0/20:0/20:4(5Z,8Z,11Z,14Z)); De Novo Triacylglycerol Biosynthesis TG(20:0/20:1(11Z)/20:4(5Z,8Z,11Z,14Z)); Glucose-6-phosphate Dehydrogenase Deficiency; De Novo Triacylglycerol Biosynthesis TG(16:1(9Z)/20:0/20:0); De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/20:1(11Z)); De Novo Triacylglycerol Biosynthesis TG(16:0/18:0/18:1(9Z)); De Novo Triacylglycerol Biosynthesis TG(16:0/18:1(9Z)/20:0); De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/20:4(5Z,8Z,11Z,14Z)); De Novo Triacylglycerol Biosynthesis TG(18:0/18:0/18:0); De Novo Triacylglycerol Biosynthesis TG(18:0/18:0/20:0); De Novo Triacylglycerol Biosynthesis TG(16:0/18:0/18:0); Glycogenosis, Type VII. Tarui Disease; De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/18:2(9Z,12Z)); De Novo Triacylglycerol Biosynthesis TG(20:0/20:1(11Z)/20:1(11Z)); De Novo Triacylglycerol Biosynthesis TG(16:0/18:0/20:0); Phosphoenolpyruvate Carboxykinase Deficiency 1 (PEPCK1); Glycerol Kinase Deficiency |
| PharmGKB | |
| ChEMBL | CHEMBL1161998 |
